Financhill
Buy
59

TECH Quote, Financials, Valuation and Earnings

Last price:
$59.14
Seasonality move :
4.15%
Day range:
$58.54 - $59.32
52-week range:
$46.01 - $79.28
Dividend yield:
0.54%
P/E ratio:
121.10x
P/S ratio:
7.68x
P/B ratio:
4.70x
Volume:
789.2K
Avg. volume:
1.7M
1-year change:
-18.83%
Market cap:
$9.2B
Revenue:
$1.2B
EPS (TTM):
$0.49

Analysts' Opinion

  • Consensus Rating
    Bio-Techne Corp. has received a consensus rating of Buy. The company's average rating is a Buy based on 11 Buy ratings, 3 Hold ratings, and 0 Sell ratings.
  • Price Target Upside
    According to analysts' consensus price target of $69.67, Bio-Techne Corp. has an estimated upside of 17.6% from its current price of $59.24.
  • Price Target Downside
    According to analysts, the lowest downside price target is $60.00 representing 100% downside risk from its current price of $59.24.

Fair Value

  • According to the consensus of 14 analysts, Bio-Techne Corp. has 17.6% upside to fair value with a price target of $69.67 per share.

TECH vs. S&P 500

  • Over the past 5 trading days, Bio-Techne Corp. has overperformed the S&P 500 by 2.05% suggesting its relative strength compared to the major market average is strong at this time.

Share Buyback

  • Bio-Techne Corp. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.

Revenue Growth

  • Bio-Techne Corp. revenues have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter Bio-Techne Corp. reported revenues of $286.6M.

Earnings Growth

  • Bio-Techne Corp. has grown year-over-year earnings for 1 quarter straight. In the most recent quarter Bio-Techne Corp. reported earnings per share of $0.24.
Enterprise value:
9.5B
EV / Invested capital:
4.02x
Price / LTM sales:
7.68x
EV / EBIT:
35.59x
EV / Revenue:
7.79x
PEG ratio (5yr expected):
--
EV / Free cash flow:
42.31x
Price / Operating cash flow:
41.70x
Enterprise value / EBITDA:
25.45x
Gross Profit (TTM):
$812.6M
Return On Assets:
2.97%
Net Income Margin (TTM):
6.41%
Return On Equity:
3.85%
Return On Invested Capital:
3.2%
Operating Margin:
17.72%
Trailing 12 Months Fiscal Quarters
Period Ending 2023-09-30 2024-09-30 2025-09-30 2024-09-30 2025-09-30
Income Statement
Revenue $1.1B $1.2B $1.2B $289.5M $286.6M
Gross Profit $775.4M $775.8M $812.6M $187.9M $190.2M
Operating Income $276.9M $244.7M $266.4M $51M $50.8M
EBITDA $386.1M $356M $372.5M $79.1M $75.1M
Diluted EPS $1.52 $0.94 $0.49 $0.21 $0.24
Period Ending 2021-09-30 2022-09-30 2023-09-30 2024-09-30 2025-09-30
Balance Sheet
Current Assets $543.7M $552M $591.5M $648.6M $609.5M
Total Assets $2.3B $2.4B $2.8B $2.7B $2.5B
Current Liabilities $134M $137.6M $127.8M $142.1M $144.5M
Total Liabilities $623.2M $599.6M $757.6M $597.4M $560.3M
Total Equity $1.6B $1.8B $2B $2.1B $2B
Total Debt $365.3M $329.4M $537.3M $385.4M $380.7M
Trailing 12 Months Fiscal Quarters
Period Ending 2023-09-30 2024-09-30 2025-09-30 2024-09-30 2025-09-30
Cash Flow Statement
Cash Flow Operations $257.7M $303.5M $251.3M $63.9M $27.6M
Cash From Investing -$400.1M -$70.6M -$12.9M -$21.7M $605K
Cash From Financing $125.9M -$205.5M -$286.5M -$11.6M -$44.2M
Free Cash Flow $215.4M $245M $224.1M $54.7M $22.2M
TECH
Sector
Market Cap
$9.2B
$27.9M
Price % of 52-Week High
74.72%
50.56%
Dividend Yield
0.54%
0%
Shareholder Yield
3.24%
-1.55%
1-Year Price Total Return
-18.83%
-17.49%
Beta (5-Year)
1.464
0.516
Dividend yield:
0.54%
Annualized payout:
$0.32
Payout ratio:
32.76%
Growth streak:
0 years

Technicals

8-day SMA
Buy
Level $58.53
200-day SMA
Buy
Level $55.21
Bollinger Bands (100)
Buy
Level 0 - 0
Chaikin Money Flow
Sell
Level --
20-day SMA
Sell
Level $59.94
Relative Strength Index (RSI14)
Sell
Level 46.89
ADX Line
Neutral
Level 0
Williams %R
Neutral
Level -42.4539
50-day SMA
Sell
Level $60.91
MACD (12, 26)
Buy
Level 16.38
25-day Aroon Oscillator
Sell
Level -56
On Balance Volume
Neutral
Level --

Financial Scores

Buy
Altman Z-Score (Annual)
Level (9.0755)
Buy
CA Score (Annual)
Level (1.2505)
Buy
Beneish M-Score (Annual)
Level (-3.0914)
Buy
Momentum Score
Level (3)
Buy
Ohlson Score
Level (-1.4425)
Buy
Piotroski F Score (Annual)
Level (6)
Buy
Quality Ratio Score
Level (8)
Buy
Fundamental Score
Level (9)

Revenue Forecast

Earnings per Share Forecast

Company Profile

Bio-Techne Corp. is a global life sciences company providing innovative tools and bioactive reagents for research and clinical diagnostic communities. Its products assist scientific investigations into biological processes and the nature and progress of specific diseases. It operates through the Protein Sciences, and Diagnostics and Spatial Biology segments. The Protein Sciences segment develops and manufactures purified proteins, and reagent solutions. The Diagnostics and Spatial Biology segment develops and manufactures diagnostic products. The company was founded in 1976 and is headquartered in Minneapolis, MN.

Stock Forecast FAQ

In the current month, TECH has received 11 Buy ratings 3 Hold ratings, and 0 Sell ratings. The TECH average analyst price target in the past 3 months is $69.67.

  • Where Will Bio-Techne Corp. Stock Be In 1 Year?

    According to analysts, the consensus estimate is that Bio-Techne Corp. share price will rise to $69.67 per share over the next 12 months.

  • What Do Analysts Say About Bio-Techne Corp.?

    Analysts are divided on their view about Bio-Techne Corp. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Bio-Techne Corp. is a Sell and believe this share price will drop from its current level to $60.00.

  • What Is Bio-Techne Corp.'s Price Target?

    The price target for Bio-Techne Corp. over the next 1-year time period is forecast to be $69.67 according to 14 Wall Street analysts, 11 of them rate the stock a Buy, 0 rate the stock a Sell, and 3 analysts rate the stock a Hold.

  • Is TECH A Buy, Sell Or Hold?

    According to Wall Street analysts, the consensus rating for Bio-Techne Corp. is a Buy. 11 of 14 analysts rate the stock a Buy at this time.

  • How Can I Buy Shares Of TECH?

    You can purchase shares of Bio-Techne Corp. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Bio-Techne Corp. shares.

  • What Is The Bio-Techne Corp. Share Price Today?

    Bio-Techne Corp. was last trading at $59.14 per share. This represents the most recent stock quote for Bio-Techne Corp.. Yesterday, Bio-Techne Corp. closed at $59.24 per share.

  • How To Buy Bio-Techne Corp. Stock Online?

    In order to purchase Bio-Techne Corp. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Why Did Stan Druckenmiller Sell Broadcom Stock?
Why Did Stan Druckenmiller Sell Broadcom Stock?

In Q3, legendary macro investor Stan Druckenmiller sold his entire…

Why Is CoreWeave Stock Down So Much?
Why Is CoreWeave Stock Down So Much?

AI cloud computing business CoreWeave (NASDAQ:CRWV) has been through a…

Why Did Stan Druckenmiller Buy MercadoLibre Stock?
Why Did Stan Druckenmiller Buy MercadoLibre Stock?

In Q3, billionaire Stan Druckenmiller bought about 4,620 shares of…

Stock Ideas

Buy
57
Is NVDA Stock a Buy?

Market Cap: $4.6T
P/E Ratio: 64x

Buy
55
Is AAPL Stock a Buy?

Market Cap: $4T
P/E Ratio: 37x

Buy
61
Is GOOG Stock a Buy?

Market Cap: $3.8T
P/E Ratio: 39x

Alerts

Sell
14
SMX alert for Dec 30

SMX (Security Matters) Plc [SMX] is down 40.26% over the past day.

Buy
71
ZCSH alert for Dec 30

Grayscale Zcash Trust (ZEC) [ZCSH] is down 4.56% over the past day.

Buy
69
GDXU alert for Dec 31

MicroSectors Gold Miners 3X Leveraged ETN [GDXU] is up 3.19% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock